Neoadjuvant chemoradiation (CRT) with or without panitumumab (Pan) in patients with K-ras-unmutated, locally advanced rectal cancer (LARC): A randomized multicenter phase II trial (SAKK 41/07).
Daniel Helbling(University Hospital of Bern), Dieter Koeberle(Kantonsspital St. Gallen), Beat Gloor(University of Bern), G. Bodoky(Unified Szent István and Szent László Hospital), Daniela Baertschi(Swiss Group For Clinical Cancer Research), Hongliang Sun, Piercarlo Saletti(Institute of Oncology Research), Oliver Gautschi(Université Toulouse III - Paul Sabatier), Fred T. Bosman(Leiden University Medical Center), Axel Madlung, Ping Yan(Jiangsu Hengrui Medicine (China)), Ralph C. Winterhalder(Luzerner Kantonsspital), L. Widmer(Triemli Hospital), Daniel Rauch(Washington University in St. Louis), Markus Borner(University of Bern), Roger Burkhard(GastroZentrum Hirslanden Zürich)
Cited by 4
Related Papers
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
|Annals of Oncology|2019|1.4k
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
|The Lancet Oncology|2013|838
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835